摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[4-chloro-3-(trifluoromethoxy)phenyl]piperazine | 1010188-90-5

中文名称
——
中文别名
——
英文名称
1-[4-chloro-3-(trifluoromethoxy)phenyl]piperazine
英文别名
1-(4-Chloro-3-trifluoromethoxyphenyl)piperazine
1-[4-chloro-3-(trifluoromethoxy)phenyl]piperazine化学式
CAS
1010188-90-5
化学式
C11H12ClF3N2O
mdl
——
分子量
280.677
InChiKey
LFIVWZOMXWJBGV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    24.5
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS<br/>[FR] DÉRIVÉS DE 5-[3-[PIPÉRAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE À UTILISER EN TANT QU'INHIBITEURS D'ADAMTS 4 ET 5 POUR TRAITER PAR EXEMPLE L'ARTHROSE
    申请人:GALAPAGOS NV
    公开号:WO2017211666A1
    公开(公告)日:2017-12-14
    The present invention discloses 5-[3-[piperazin-l-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives according to Formula (I), wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS 4 and 5 for the prophylaxis or treatment of inflammatory diseases or diseases involving degradation of cartilage or disruption of cartilage homeostasis, such as e.g. osteoarthritis.
    本发明公开了根据式(I)的5-[3-[哌嗪-1-基]-3-氧代-丙基]-咪唑啉-2,4-二酮衍生物,其中R1、R2、R3a、R3b、R6a、R6b、下标n和Cy如本文所定义。本发明涉及抑制ADAMTS 4和5的化合物,用于预防或治疗炎症性疾病或涉及软骨降解或破坏软骨稳态的疾病,例如骨关节炎。
  • 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES
    申请人:Zhang Penglie
    公开号:US20100069396A1
    公开(公告)日:2010-03-18
    Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 4-amino-3-imidazoyl-pyrazolo[3,4-d]pyrimidine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    提供了作为CCR1受体的有效拮抗剂的化合物,并具有体内抗炎活性。这些化合物是4-基-3-咪唑吡唑并[3,4-d]嘧啶生物,可用于制备药物组合物,治疗CCR1介导的疾病的方法,以及作为竞争性CCR1拮抗剂鉴定的控制。
  • 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines
    申请人:——
    公开号:US08343975B2
    公开(公告)日:2013-01-01
    Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 4-amino-3-imidazoyl-pyrazolo[3,4-d]pyrimidine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    提供了一些化合物,作为CCR1受体的有效拮抗剂,并在体内具有抗炎活性。这些化合物是4-基-3-咪唑基-吡唑并[3,4-d]嘧啶生物,可用于制备药物组合物、治疗CCR1介导的疾病的方法,以及作为竞争性CCR1拮抗剂鉴定的控制。
  • 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis
    申请人:Galapagos NV
    公开号:US10829478B2
    公开(公告)日:2020-11-10
    The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.
    本发明公开了符合式 I 的化合物: 其中R1、R2、R3a、R3b、R6a、R6b、下标n和Cy如本文所定义。 本发明涉及抑制 ADAMTS 的化合物、其生产方法、包含本发明化合物的药物组合物和使用本发明化合物的治疗方法,通过施用本发明化合物预防和/或治疗炎症性疾病和/或涉及软骨降解和/或破坏软骨稳态的疾病。
  • 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS
    申请人:Galapagos NV
    公开号:EP3468955B1
    公开(公告)日:2021-01-06
查看更多